Citation Information :
Sarkar A, Mahapatra M, Parija J, Pattnaik S. A Case Series of Peritonectomy done in Different Histopathological Patterns of Ovarian Cancer Cases: A Critical Analysis. J South Asian Feder Obs Gynae 2021; 13 (5):297-300.
Background: Peritoneal dissemination is the most common mode of spread for cancer ovary. Total peritonectomy (PRT) refers to removal of all peritoneum and total omentectomy. Here we have analyzed PRT in five different histopathological variants of ovarian cancer.
Case descriptions: Five different cases were operated in our institute in last 1 month. All are having different histopathological patterns and underwent cytoreductive surgery (CRS) with PRT achieving surgical complexity score (SCS) of 8. They were not associated with any major complications due to proper PRT. PRT has been done here by blunt dissection.
Discussion: The PRT is feasible with acceptable complication rate and hospital duration. In our case series, only two people had major injury that too due to the tumor properly not due to PRT.
Conclusion: The PRT must be done in all cases of carcinoma ovary as part of the CRS procedure. It is reproducible, feasible, and without much complication.
Glockzin G, Rochon J, Arnold D, et al. A prospective multicenter phase II study evaluating multimodality treatment of patients with peritoneal carcinomatosis arising from appendiceal and colorectal cancer: the COMBATAC trial. BMC Cancer 2013;13:67. DOI: 10.1186/1471-2407-13-67.
DeVita VT Jr, Lawrence TS, Rosenberg SA, editors. DeVita, Hellman, and Rosenberg's cancer: principles and practice of oncology. 9th ed. Philadelphia: Wolters Kluwer Health/Lippincott Williams & Wilkins; 2011. p. 2081–2089.
Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci 2001;56(3):M146–M156. DOI: 10.1093/gerona/56.3.m146.
Votanopoulos KI, Newman NA, Russell G, et al. Outcomes of cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemo-therapy (HIPEC) in patients older than 70 years; survival benefit at considerable morbidity and mortality. Ann Surg Oncol 2013;20(11):3497–3503. DOI: 10.1245/s10434-013-3053-z.
Stephens AD, Alderman R, Chang D, et al. Morbidity and mortality analysis of 200 treatments with cytoreductive surgery and hyperthermic intraoperative intraperitoneal chemotherapy using the coliseum technique. Ann Surg Oncol 1999;6(8):790–796. DOI: 10.1007/s10434-999-0790-0.
Baratti D, Passot G, Beaujard AC. Hyperthermic intraperitoneal chemotherapy: Nomenclature and modalities of perfusion. J Surg Oncol 2008;98(4):242–246. DOI: 10.1002/jso.21061.
Samel S, Singal A, Becker H, et al. Problems with intraoperative hyperthermic peritoneal chemotherapy for advanced gastric cancer. Eur J Surg Oncol (EJSO) 2000;26(3):222–226. DOI: 10.1053/ejso.1999.0780.
Ferron G, Dattez S, Gladieff L, et al. Pharmacokinetics of heated intraperitoneal oxaliplatin. Cancer Chemother Pharmacol 2008;62(4):679–683. DOI: 10.1007/s00280-007-0654-x.